RhumbLine Advisers
CASI

RhumbLine Advisers’s CASI Pharmaceuticals CASI Stock Holding History

RhumbLine Advisers’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,159
Closed -$172K – 3004
2021
Q1 		$172K Sell
7,159
-170
-2% -$4.77K ﹤0.01% 2863
2020
Q4 		$216K Buy
7,329
+754
+11% +$16.4K ﹤0.01% 2807
2020
Q3 		$101K Sell
6,575
-828
-11% -$15.6K ﹤0.01% 2869
2020
Q2 		$185K Buy
7,403
+847
+13% +$18.4K ﹤0.01% 2798
2020
Q1 		$134K Hold
6,556
– – ﹤0.01% 2709
2019
Q4 		$203K Buy
6,556
+17
+0.3% +$551 ﹤0.01% 2742
2019
Q3 		$218K Buy
6,539
+26
+0.4% +$835 ﹤0.01% 2719
2019
Q2 		$208K Buy
6,513
+138
+2% +$4.41K ﹤0.01% 2774
2019
Q1 		$183K Sell
6,375
-65
-1% -$2.27K ﹤0.01% 2768
2018
Q4 		$259K Buy
6,440
+2,157
+50% +$81.7K ﹤0.01% 2609
2018
Q3 		$200K Sell
4,283
-262
-6% -$18.3K ﹤0.01% 2729
2018
Q2 		$374K Buy
+4,545
New +$307K ﹤0.01% 2437

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's CASI Position: Q2 2021 in Review

RhumbLine Advisers sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 7,159 shares — an estimated $172K sold.

RhumbLine Advisers first reported a position in CASI in Q2 2018 and held it in 12 quarters. The position peaked at $374K in Q2 2018. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

  • RhumbLine Advisers reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 7,159 CASI Pharmaceuticals shares in Q2 2021, an estimated $172K.
  • RhumbLine Advisers first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • RhumbLine Advisers's CASI Pharmaceuticals position peaked at $374K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.